Similar articles

• Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone.

  Stempel DA, Raphiou IH, Kral KM, Yeakey AM, Emmett AH, Prazma CM, Buaron KS, Pascoe SJ; AUSTRI Investigators. Stempel DA, et al. N Engl J Med. 2016 May 12;374(19):1822-30. doi: 10.1056/NEJMoa1511049. Epub 2016 Mar 6. N Engl J Med. 2016. PMID: 26949137 Clinical Trial.
• Investigation of the efficacy of generic and brand-name salmeterol/fluticasone combination in the management of asthma: a randomized comparative trial.

  Panahi Y, Ghanei M, Maghsoudi H, Saffar Soflaei S, Sahebkar A. Panahi Y, et al. Acta Biomed. 2018 Jun 7;89(2):186-192. doi: 10.23750/abm.v89i2.5411. Acta Biomed. 2018. PMID: 29957750 Free PMC article. Clinical Trial.
• Comparative Analysis of Persistence to Treatment among Patients with Asthma or COPD Receiving AirFluSal Forspiro or Seretide Diskus Salmeterol/Fluticasone Propionate Combination Therapy.

  Bender BG, Hernandez Vecino RA, McGrath K, Jones S. Bender BG, et al. J Allergy Clin Immunol Pract. 2016 Sep-Oct;4(5):884-9. doi: 10.1016/j.jaip.2016.07.006. J Allergy Clin Immunol Pract. 2016. PMID: 27587319
• Inhaled salmeterol/fluticasone propionate: a review of its use in asthma.

  Reynolds NA, Lyseng-Williamson KA, Wiseman LR. Reynolds NA, et al. Drugs. 2005;65(12):1715-34. doi: 10.2165/00003495-200565120-00012. Drugs. 2005. PMID: 16060707 Review.
• Seretide: a pharmacoeconomic analysis.

  Fritscher L, Chapman KR. Fritscher L, et al. J Med Econ. 2008;11(3):555-70. doi: 10.3111/13696990802320908. J Med Econ. 2008. PMID: 19450105 Review.